Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia
Topic overview
This study investigates intra-amniotic administration of sildenafil and rosiglitazone as prenatal interventions to reduce pulmonary vascular remodeling and improve blood flow in congenital diaphragmatic hernia. The research explores whether late-gestation pharmacologic treatment can mitigate the challenging pulmonary hypertension complications that persist after birth in CDH patients.
Key takeaways
- Pulmonary hypertension is a major management challenge in congenital diaphragmatic hernia (CDH).
- Prenatal intra-amniotic therapy may reduce postnatal pulmonary hypertension in CDH.
- Sildenafil (PDE5 inhibitor) and rosiglitazone (PPAR-γ agonist) are candidate prenatal therapies.
- Late-gestation treatment aims to reverse pulmonary vascular remodeling and improve peripheral blood flow.
- This approach represents a potential prenatal intervention strategy for CDH-associated pulmonary hypertension.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Intra-Amniotic Sildenafil and Rosiglitazone Late in Gestation Ameliorate the Pulmonary Hypertension Phenotype in Congenital Diaphragmatic Hernia. GlobalCastMD Medical Library. 2024-01-22. https://library.globalcastmd.com/article/8246
Comments